COMPASS Pathways plc was originally incorporated as a private limited company under the laws of England and Wales in June 2020. The company is a biotechnology company dedicated to accelerating patient access to innovative evidence-based mental health therapies. The company is pioneering a new paradigm for treating mental health conditions with a focus on rapid and durable responses by developing their investigational COMP 360 psilocybin treatment, which may be the first of its kind. COMP 360 is their proprietary psilocybin formulation, which includes their pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.
